Moleculin Biotech Inc

Research Moleculin Biotech Inc (MBRX) on Bullrun: market cap USD 19.05M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerMBRX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 19.05M
• Financial periodFY2025
• Net income-USD 33.56M
• Free cash flow-USD 22.74M

Valuation Snapshot

latest market cap is USD 19.05M.

About Moleculin Biotech Inc

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.

Frequently asked questions

What is Moleculin Biotech Inc's market cap?

Moleculin Biotech Inc's market capitalization is USD 19.05M.

What does Moleculin Biotech Inc do?

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses.